{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:48:28Z","timestamp":1781848108216,"version":"3.54.5"},"reference-count":12,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Conjunctivitis is an inflammation of the conjunctiva, a thin translucent mucous membrane, characterized by a dilatation of the conjunctival vessels. Causes leading to conjunctivitis are diverse, being drug related one of them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a case of an 80-year-old man with a diagnosis of relapsed stage IV colon cancer who developed a severe conjunctivitis, scar ectropion with lack of tissue and eversion of the subconjunctival conjunctiva after being treated with capecitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Capecitabine was discontinued and pharmacological treatment was initiated with a complete resolution of the symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Ocular toxicity derived from the use of systemic fluorouracil has been widely described in the literature, as well as the relationship between the use of capecitabine and the appearance of conjunctivitis. However, the development of severe conjunctivitis with other complications has not been previously reported. Monitor patients closely and perform full medication assessment should be undertaken when a patient reports visual changes to manage toxicity in the early stages. Following the patient evaluation and evolution and based on the Karch Lasanga algorithm modified by Naranjo, the adverse reaction is considered as probable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221078790","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:51:21Z","timestamp":1649047881000},"page":"1889-1892","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-741X","authenticated-orcid":false,"given":"Marta","family":"Bello Crespo","sequence":"first","affiliation":[{"name":"Pharmacy Department, Manacor Hospital, Manacor, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Trujillano Ruiz","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Manacor Hospital, Manacor, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Gajete Pablos","sequence":"additional","affiliation":[{"name":"Oncology Department, Manacor Hospital, Manacor, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Marcela","family":"Roa Garc\u00eda","sequence":"additional","affiliation":[{"name":"Oncology Department, Manacor Hospital, Manacor, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n Andr\u00e9s","family":"Gioseffi","sequence":"additional","affiliation":[{"name":"Oncology Department, Manacor Hospital, Manacor, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"bibr1-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008033430507"},{"key":"bibr2-10781552221078790","unstructured":"Yanoff M, Duker J. Ophthalmology 5th Edition [Internet]. [cited 2020 Nov 13]. 1440 p. Available from: https:\/\/www.elsevier.com\/books\/ophthalmology\/yanoff\/978-0-323-52819-1"},{"key":"bibr3-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280318"},{"key":"bibr4-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2015.05.001"},{"key":"bibr5-10781552221078790","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831020-00003"},{"key":"bibr6-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2010.05.001"},{"key":"bibr7-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr8-10781552221078790","volume-title":"CIMA (Centro de informaci\u00f3n de medicamentos). Ficha t\u00e9cnica de Xeloda\u00ae 500\u2005mg (dalbavancina) [Base de datos en Internet]","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"key":"bibr9-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"bibr10-10781552221078790","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009073431015"},{"key":"bibr11-10781552221078790","doi-asserted-by":"publisher","DOI":"10.4103\/JCAS.JCAS_5_18"},{"key":"bibr12-10781552221078790","unstructured":"Notificaci\u00f3n de sospechas de reacciones adversas [Internet]. Espa\u00f1a: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios; 15 de enero de 2013 [Consultado 18 de noviembre de 2020]. Disponible en: https:\/\/www.notificaram.es\/Pages\/CCAA.aspx#no-back-button."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221078790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221078790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221078790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:38Z","timestamp":1777688798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221078790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10781552221078790"],"URL":"https:\/\/doi.org\/10.1177\/10781552221078790","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]}}}